# Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer

> **NCT01051167** · PHASE2 · COMPLETED · sponsor: **Martin Schuler, Prof. Dr. med.** · enrollment: 59 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01051167
- **Lead sponsor:** Martin Schuler, Prof. Dr. med.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051167, "Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01051167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*